Longer term holders than me (early 2019) may be able to enlighten me whatever became of the 2016 proposal to cross list on NASDAQ.
Obviously, getting human/canine trials running will cost big bucks. A further 10% dilution doesn't sit well with most holders.
Does anyone else think that re-visiting a NASDAQ listing could be a potential solution to funding trials now that the Elanco option is defunct?
I don't know the circumstances surrounding the 2016 attempt. Surely we are in a stronger position now. An IPO could raise sufficient capital to progress our trials as well as broaden our reputation.
Happy to hear any thoughts...
Good luck to all holders, Thrifty
PharmAust - Now that is impressive, page-108
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.010(5.13%) |
Mkt cap ! $99.65M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 20.5¢ | 19.5¢ | $95.38K | 475.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 135256 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 79851 | 3 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |